SPINEGUARD Stock: price and directors' dealings · France · AMF

About SPINEGUARD

SpineGuard is a French medical technology company focused on spine surgery and, more broadly, bone-surgery guidance solutions. Founded in 2009 by Pierre Jérôme and Stéphane Bette, the company developed a proprietary platform called DSG® (Dynamic Surgical Guidance), which uses real-time local electrical conductivity sensing to help surgeons secure and simplify the placement of bone implants. SpineGuard is listed on Euronext Growth Paris under the ticker ALSGD, with ISIN FR0011464452, and it is headquartered in Vincennes, France, while maintaining an operational presence in Boulder, Colorado, in the United States. The company positions itself as a niche specialist at the intersection of medtech, smart surgical instrumentation and data-driven procedural assistance. SpineGuard’s core business is built around the PediGuard® family of drilling instruments, which embed DSG technology. These devices are designed to provide immediate sensory feedback to surgeons during pedicle preparation, with the goals of improving accuracy, reducing the risk of cortical breach and lowering exposure to X-ray radiation in the operating room. The product portfolio also includes variants adapted to different surgical needs, such as straight, curved, threaded and cannulated versions, as well as developments linked to robotics and new orthopedic applications. From a scientific and commercial standpoint, SpineGuard has accumulated a meaningful clinical track record, with more than 500,000 pedicle screws placed worldwide using its devices and numerous peer-reviewed publications supporting the technology. This evidence base is a key part of the company’s value proposition to surgeons, hospitals and industrial partners. Growth is pursued through geographic expansion, intellectual-property reinforcement and partnerships for distribution and industrial deployment. In 2025, SpineGuard continued its operational transformation in a still-challenging environment for small-cap medtech companies. The company reported 2025 revenue of €3.758 million, down 19% year on year, while also improving its operating performance and extending its cash runway into 2026-2027 according to recent communications. The year was also marked by strategic progress in North America, Europe and Asia, along with new commercial agreements, underscoring a business model centered on innovation, IP protection and the gradual scaling of its technologies.